Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Net Income · Q2 FY2027 · quarter ended Sep 2026

Net income declines year over year

Q2 FY2027 net income of ₹9.24B fell 35.3% year over year, ahead of the -52.4% change in trailing-twelve-month net income. Sequentially, it rose 112.5% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Net income amounted to 12.8% of revenue in FY2026, down 4.8 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 18 analysts of ₹36.58B (-18.9%) for the fiscal year ending Mar 2027, a step up from the -21.2% reported in FY2026.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
₹9.24B+112.5% QoQ
Last fiscal yearMar 2026
₹45.09B-21.2% YoY
LTMSep 2026
₹27.72B-52.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.3%-15.7%+19.6 pp
1 year-21.2%-18.9%+2.4 pp
3-year CAGR+0.0%+10.9%+10.9 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

INR · from the cash flow

Latest · FY2026
45.09B INR
Year-over-year change
-21.2%
4-year CAGR
+17.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -52.4% is the 6th highest of 8, against a peer median of +13.1%.
  • Net income amounts to 8.4% of revenue for RDY, versus a peer median of 9.8%.
RDY Competitors
Net Income for RDY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹27.72B INR-52.4%+0.0%8.4%
HLNHaleon plcFY2025£1.63B GBP+13.1%+13.4%14.8%
BHCBausch Health Companies Inc.LTM Jun 2026$1.1B USD-2132.0%—10.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$709M USD+537.7%—4.1%
VTRSViatris Inc.LTM Jun 2026$410.7M USD-88.2%—2.8%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$215.32M USD+320.2%—6.9%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$90.09M USD+528.0%—9.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$79.23M USD-44.1%+2.4%11.0%
Peer median (excluding RDY) —+13.1%+7.9%9.8%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income23.57B45.07B55.68B57.25B45.09B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
Deferred Income Tax8.73B15.3B16.19B19.54B0
Stock-Based Compensation592M397M407M424M0
Change in Working Capital(13.91B)(7.86B)(20.18B)(29.99B)(12.24B)
Accounts Receivables(17.01B)(5.75B)(8.05B)(10.28B)(7.07B)
Inventory(5.33B)(2.65B)(18.45B)(12.75B)(9.05B)
Accounts Payables17.01B0002.94B
Other Working Capital(8.59B)551M6.32B(6.95B)943.83M
Other Non-Cash Items(2.69B)(6.67B)(21.5B)(17.85B)2.12B
Operating Cash Flow28.11B58.88B45.43B46.43B56.65B
Capital Expenditures(19.05B)(18.87B)(27.44B)(34.4B)(24.54B)
Acquisitions (Net)(326M)0(12M)(53.41B)(2.99B)
Purchases of Investments(88.97B)(136.17B)(145.49B)(254.46B)(49.21B)
Sales of Investments77.77B112.81B129.78B279.58B20.63B
Other Investing Activities4.19B(6.68B)(8.16B)(2.28B)1.47B
Investing Cash Flow(26.39B)(41.37B)(40.28B)(58.08B)(70.53B)
Debt Repayment2.74B(20.4B)4.35B23.2B21.31B
Common Stock Issued334M368M805M193M417.73M
Common Stock Repurchased000(1.39B)0
Dividends Paid(4.15B)(4.98B)(6.65B)(6.66B)(7.01B)
Other Financing Activities(1.35B)(1.85B)(2.27B)3.57B(1.33B)
Financing Cash Flow(2.42B)(26.86B)(3.76B)18.91B13.4B
Effect of Forex Changes733M286M(59M)224M(383.41M)
Net Change in Cash32M(9.07B)1.33B7.49B(875.84M)
Free Cash Flow9.06B40.01B18B12.03B32.1B

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.